Linfoma no Hodgkin

+ -Text Size

Otros recursos y referencias TEMAS

Referencias: guía detallada del linfoma no Hodgkin

American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga: American Cancer Society; 2014.

Dunleavy K, Wilson WH. Diagnosis and treatment of non-Hodgkin lymphoma (aggressive). In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Elsevier; 2009:1293-1302.

Evens AM, Winter JN, Gordon LI, et al. Non-Hodgkin lymphoma. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach. 13th ed. Lawrence, KS: UBM Medica; 2010:739-794.

Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30(24):2988-2994.

Friedberg JW, Mauch PM, Rimsza LM, Fisher RI. Non-Hodgkin lymphomas. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1855-1893.

Gribben JG. Clinical manifestations, staging, and treatment of indolent non-Hodgkin’s lymphoma. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Elsevier; 2009:1281-1292.

Hartge P, Smith MT. Environmental and behavioral factors and the risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:367-368.

Hawkes EA, Wotherspoon A, Cunningham D. Diagnosis and management of rare gastrointestinal lymphomas. Leuk Lymphoma. 2012 Dec;53(12):2341-2350. Epub 2012 Jun 21.

Howlader N, Noone AM, Krapcho M (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.

Jaffe ES, Pittaluga S. The pathologic basis for the classification of non-Hodgkin’s lymphoma. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Elsevier; 2009:1265-1280.

Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009;27:2983-2990.

Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053-4061.

Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States 1992-2001. Blood. 2006;107:265-276.

National Cancer Institute. Physician Data Query (PDQ). Adult Non-Hodgkin Lymphoma Treatment. 4/11/2014. Accessed at www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/healthprofessional on June 27, 2014.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas. Version 2.2014. Accessed at www.nccn.org on June 30, 2014.

Pro B, Advani R, Brice P, et al.Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196. Epub 2012 May 21.

Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood. 2006;107:1255-1264.

Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29(20):2787-2794.

Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-1861.

Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004;104:1258-1265.

Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 8;369(6):507-16. Epub 2013 Jun 19.

Roschewski MJ, Wilson WH. Non-Hodgkin’s Lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014:2033-2059.

Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev. 2009;(2):CD006552.


Fecha de última actualización: 09/30/2014
Fecha de último cambio o revisión: 09/30/2014